Sanara MedTech Inc. (NASDAQ: SMTI) is a company focused on medical technology, aiming to improve clinical outcomes and reduce healthcare costs in the surgical market. Despite its innovative approach, SMTI reported disappointing financial results for the third quarter of 2025. The company announced an earnings per share (EPS) of -$3.40, significantly missing the estimated EPS of -$0.24.
The company's revenue for the quarter was $26.3 million, falling short of the expected $29.9 million. However, this figure still represents a 22% increase from the $21.7 million reported in the same quarter of 2024. This growth is part of SMTI's ongoing efforts to develop and commercialize transformative technologies in the healthcare sector.
Despite the revenue growth, SMTI's financial metrics indicate challenges. The company has a negative price-to-earnings (P/E) ratio of approximately -18.30, reflecting its current losses. The price-to-sales ratio is about 1.93, suggesting that investors are willing to pay $1.93 for every dollar of sales, while the enterprise value to sales ratio is around 2.23.
SMTI's enterprise value to operating cash flow ratio is notably high at approximately 59.33, indicating a premium valuation compared to its cash flow. The company also has a negative earnings yield of about -5.47%, further highlighting its unprofitability. The debt-to-equity ratio stands at approximately 1.28, suggesting a moderate level of debt compared to equity.
On a positive note, SMTI's current ratio is around 2.26, indicating a strong ability to cover short-term liabilities with short-term assets. This financial stability is crucial as the company navigates its strategic direction, as discussed in its recent Q3 2025 earnings call attended by key company leaders and analysts.
